Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID PRESCOTT TIETJEN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1508838384
CMS profile
159288
Location
HUNTSVILLE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$279.61

18 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $279.61 18

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID PRESCOTT TIETJEN

NPI 1508838384 · CMS profile ID 159288

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

HUNTSVILLE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508838384?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508838384?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508838384?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1508838384?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

18 matching records · $279.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 18 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–18 of 18.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
OPKO Pharmaceuticals, LLC $15.2611/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752238093 CMS
AstraZeneca Pharmaceuticals LP $13.9211/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736383989 CMS
Horizon Therapeutics plc $15.0011/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721448721 CMS
AstraZeneca Pharmaceuticals LP $18.9309/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736274835 CMS
Relypsa, Inc. $13.8409/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742199549 CMS
Novartis Pharmaceuticals Corporation $15.5707/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726160769 CMS
OPKO Pharmaceuticals, LLC $11.9907/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752238089 CMS
Alexion Pharmaceuticals, Inc. $14.4607/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726636247 CMS
AKEBIA THERAPEUTICS INC $18.5806/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753171637 CMS
Relypsa, Inc. $12.3105/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742204009 CMS
OPKO Pharmaceuticals, LLC $14.4003/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752238095 CMS
AKEBIA THERAPEUTICS INC $16.4903/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753171635 CMS
Otsuka America Pharmaceutical, Inc. $23.0802/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748801989 CMS
OPKO Pharmaceuticals, LLC $19.7502/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752238091 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.7702/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747312973 CMS
Otsuka America Pharmaceutical, Inc. $16.5701/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748801987 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.2001/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747312971 CMS
AstraZeneca Pharmaceuticals LP $12.4901/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736245931 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $462.83 30
PY2020 $279.61 18
PY2021 $646.77 24
PY2022 $630.15 34
PY2023 $655.62 29
PY2024 $538.52 20
PY2025 $311.01 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $86,493.87 37
PY2024 Principal investigator $77,411.65 31
PY2023 Principal investigator $244,765.38 77
PY2022 Principal investigator $437,199.28 132
PY2021 Principal investigator $475,627.60 160
PY2020 Principal investigator $841,410.33 80
PY2019 Principal investigator $476,990.58 451

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

132 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 12/19/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292197
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 12/19/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292203
Principal investigator 1 Ardelyx, Inc. $250.00 12/19/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150721
Principal investigator 1 Alexion Pharmaceuticals, Inc. $80.00 12/16/2022 Non-covered Recipient Entity
APOGEE CLINICAL RESEARCH LLC
Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 914596663
Principal investigator 1 AstraZeneca UK Limited $141,588.91 12/05/2022 Non-covered Recipient Entity
APOGEE CLINICAL RESEARCH LLC
A Phase 2b multicentre randomized double-blind placebo-controlled parallel group dose ranging study to assess the efficacy safety and tolerability of zibotentan and dapagliflozin in patients with chronic kidney disease with estimated glomerular filtration rate eGFR between 20 and 60 mL min 1.73 m2 No dispute reported 06/30/2026 914598039
Principal investigator 1 AKEBIA THERAPEUTICS INC $229.50 11/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292195
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 11/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292205
Principal investigator 1 CSL Behring $120.00 11/15/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271849
Principal investigator 1 Boehringer Ingelheim International GmbH $5,936.80 10/26/2022 Non-covered Recipient Entity
Nephrology Consultants
Slope Estimation and Homogeneity Study No dispute reported 06/30/2026 946883669
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 10/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292199
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 10/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292201
Principal investigator 1 CSL Behring $264.00 10/11/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271829
Principal investigator 1 CSL Behring $96.00 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271827
Principal investigator 1 CSL Behring $240.00 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271831
Principal investigator 1 CSL Behring $212.50 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271833
Principal investigator 1 CSL Behring $120.00 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271835
Principal investigator 1 CSL Behring $212.50 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271837
Principal investigator 1 CSL Behring $120.00 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271839
Principal investigator 1 CSL Behring $120.00 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271841
Principal investigator 1 CSL Behring $85.50 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271843
Principal investigator 1 CSL Behring $160.00 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271845
Principal investigator 1 CSL Behring $30.00 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271847
Principal investigator 1 CSL Behring $256.00 10/06/2022 Non-covered Recipient Entity
Nephrology Consultants, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950271851
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,500.00 10/03/2022 Non-covered Recipient Entity
Nephrology Consultants LLC
MRD in CKD Patients PoCP Study No dispute reported 06/30/2026 949199909
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 09/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292103
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 09/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292105
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 09/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292107
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 09/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292109
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 09/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292111
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 09/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292113
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 09/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292115
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $39.00 09/08/2022 Non-covered Recipient Entity
Nephrology Consultants
PoCP study in FSGS No dispute reported 06/30/2026 965112493
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292079
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,680.50 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292081
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292083
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292085
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292087
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292089
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292091
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292093
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292095
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292097
Principal investigator 1 AKEBIA THERAPEUTICS INC $78.41 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292099
Principal investigator 1 AKEBIA THERAPEUTICS INC $800.00 08/17/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292101
Principal investigator 1 Ardelyx, Inc. $375.00 08/17/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926150655
Principal investigator 1 Boehringer Ingelheim International GmbH $191.80 08/01/2022 Non-covered Recipient Entity
Nephrology Consultants
PoCP study in FSGS No dispute reported 06/30/2026 965112615
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 07/25/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292075
Principal investigator 1 AKEBIA THERAPEUTICS INC $300.00 07/25/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292077
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,200.00 06/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292073
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 05/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292061
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 05/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292063
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 05/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292065
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 05/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292067
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 05/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292069
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,250.00 05/23/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292071
Principal investigator 1 Ardelyx, Inc. $1,500.00 05/23/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Randomized, Open-Label Study to Evaluate the Use of Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis who are Phosphate Binder Naive or on Phosphate Binder Therapy, to Optimize Phosphorus No dispute reported 06/30/2026 926149827
Principal investigator 1 Ardelyx, Inc. $1,000.00 05/23/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Randomized, Open-Label Study to Evaluate the Use of Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis who are Phosphate Binder Naive or on Phosphate Binder Therapy, to Optimize Phosphorus No dispute reported 06/30/2026 926149829
Principal investigator 1 Ardelyx, Inc. $500.00 05/23/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Randomized, Open-Label Study to Evaluate the Use of Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis who are Phosphate Binder Naive or on Phosphate Binder Therapy, to Optimize Phosphorus No dispute reported 06/30/2026 926149831
Principal investigator 1 Ardelyx, Inc. $750.00 05/23/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Randomized, Open-Label Study to Evaluate the Use of Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis who are Phosphate Binder Naive or on Phosphate Binder Therapy, to Optimize Phosphorus No dispute reported 06/30/2026 926149835
Principal investigator 1 Ardelyx, Inc. $1,794.00 05/23/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Randomized, Open-Label Study to Evaluate the Use of Tenapanor as the Core Therapy in the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis who are Phosphate Binder Naive or on Phosphate Binder Therapy, to Optimize Phosphorus No dispute reported 06/30/2026 926149837
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292039
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,498.50 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292041
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,498.50 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292043
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292045
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292047
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292049
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292051
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292053
Principal investigator 1 AKEBIA THERAPEUTICS INC $600.00 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292055
Principal investigator 1 AKEBIA THERAPEUTICS INC $597.38 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292057
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 04/20/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292059
Principal investigator 1 Ardelyx, Inc. $1,500.00 04/20/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination with Sevelamer to Treat to Goal Serum Phosphorus in Patients with End-Stage Renal Disease on Dialysis (NORMALIZE) No dispute reported 06/30/2026 926149569
Principal investigator 1 Ardelyx, Inc. $1,000.00 04/20/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination with Sevelamer to Treat to Goal Serum Phosphorus in Patients with End-Stage Renal Disease on Dialysis (NORMALIZE) No dispute reported 06/30/2026 926149571
Principal investigator 1 Ardelyx, Inc. $1,000.00 04/20/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination with Sevelamer to Treat to Goal Serum Phosphorus in Patients with End-Stage Renal Disease on Dialysis (NORMALIZE) No dispute reported 06/30/2026 926149573
Principal investigator 1 Ardelyx, Inc. $20.16 04/20/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination with Sevelamer to Treat to Goal Serum Phosphorus in Patients with End-Stage Renal Disease on Dialysis (NORMALIZE) No dispute reported 06/30/2026 926149579
Principal investigator 1 Ardelyx, Inc. $1,500.00 04/20/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination with Sevelamer to Treat to Goal Serum Phosphorus in Patients with End-Stage Renal Disease on Dialysis (NORMALIZE) No dispute reported 06/30/2026 926149681
Principal investigator 1 Ardelyx, Inc. $1,000.00 04/20/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149697
Principal investigator 1 Ardelyx, Inc. $1,500.00 04/20/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149699
Principal investigator 1 Alexion Pharmaceuticals, Inc. $22,095.35 04/06/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS, LLC
Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 914600651
Principal investigator 1 Boehringer Ingelheim International GmbH $3,688.10 03/31/2022 Non-covered Recipient Entity
Nephrology Consultants
Slope Estimation and Homogeneity Study No dispute reported 06/30/2026 946883675
Principal investigator 1 GlaxoSmithKline, LLC. $2,193.75 03/25/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943947995
Principal investigator 1 GlaxoSmithKline, LLC. $3,251.30 03/23/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943947991
Principal investigator 1 AKEBIA THERAPEUTICS INC $634.50 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292017
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292019
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292021
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292023
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292025
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292027
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292029
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292031
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,792.14 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292033
Principal investigator 1 AKEBIA THERAPEUTICS INC $229.50 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292035
Principal investigator 1 AKEBIA THERAPEUTICS INC $675.00 03/22/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292037
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,354.55 03/01/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS, LLC
A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease No dispute reported 06/30/2026 914604357
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291967
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291969
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,498.50 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291971
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,201.50 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291973
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,201.50 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291975
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,498.50 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291977
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291979
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291981
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291983
Principal investigator 1 AKEBIA THERAPEUTICS INC $634.50 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291985
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291987
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,000.00 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291989
Principal investigator 1 AKEBIA THERAPEUTICS INC $597.38 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292013
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,900.00 02/18/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885292015
Principal investigator 1 Ardelyx, Inc. $250.00 02/18/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149395
Principal investigator 1 Ardelyx, Inc. $250.00 02/18/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149397
Principal investigator 1 Ardelyx, Inc. $250.00 02/18/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149399
Principal investigator 1 Ardelyx, Inc. $250.00 02/18/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149401
Principal investigator 1 Ardelyx, Inc. $250.00 02/18/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149403
Principal investigator 1 Ardelyx, Inc. $625.00 02/18/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149405
Principal investigator 1 Ardelyx, Inc. $500.00 02/18/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149407
Principal investigator 1 AstraZeneca UK Limited $2,750.49 02/17/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS, LLC
A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease No dispute reported 06/30/2026 914600047
Principal investigator 1 GlaxoSmithKline, LLC. $13,404.30 02/16/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943947997
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/11/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943947993
Principal investigator 1 Horizon Therapeutics plc $3,070.00 02/07/2022 Non-covered Recipient Entity
FRENOVA LLC
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF PEGLOTICASE IN PATIENTS WITH UNCONTROLLED GOUT WHO HAVE UNDERGONE KIDNEY TRANSPLANTATION No dispute reported 06/30/2026 937593383
Principal investigator 1 GlaxoSmithKline, LLC. $8,290.62 02/04/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943947999
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $48,795.73 01/31/2022 Non-covered Recipient Entity
Nephrology Consultants
EMPA KIDNEY No dispute reported 06/30/2026 946865721
Principal investigator 1 Boehringer Ingelheim International GmbH $62,180.00 01/24/2022 Non-covered Recipient Entity
Nephrology Consultants
EMPA KIDNEY No dispute reported 06/30/2026 946883663
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 01/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291949
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 01/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291951
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,640.25 01/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291953
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,599.75 01/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291955
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,599.75 01/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291957
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,653.75 01/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291959
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,134.00 01/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291961
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,194.76 01/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291963
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 01/21/2022 Non-covered Recipient Entity
Apogee Clinical Research, LLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885291965
Principal investigator 1 Ardelyx, Inc. $737.10 01/21/2022 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
STUDY TO EVALUATE THE USE OF TENAPANOR AS CORE THERAPY IN THE TREATMENT OF HYPERPHOSPHATEMIA (OPTIMIZE) No dispute reported 06/30/2026 926149293